Jacques Médioni

10.4k total citations
125 papers, 3.3k citations indexed

About

Jacques Médioni is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Jacques Médioni has authored 125 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Pulmonary and Respiratory Medicine, 53 papers in Oncology and 26 papers in Molecular Biology. Recurrent topics in Jacques Médioni's work include Renal cell carcinoma treatment (28 papers), Cancer Treatment and Pharmacology (16 papers) and Renal and related cancers (14 papers). Jacques Médioni is often cited by papers focused on Renal cell carcinoma treatment (28 papers), Cancer Treatment and Pharmacology (16 papers) and Renal and related cancers (14 papers). Jacques Médioni collaborates with scholars based in France, United States and Spain. Jacques Médioni's co-authors include Stéphane Oudard, Laure Fournier, Eugéniu Banu, Bernard Escudier, Antoine M. Dujon, Marc Riquet, Françoise Le Pimpec‐Barthes, C.A. Cuénod, D Manac'h and R. Thiam and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Jacques Médioni

113 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jacques Médioni France	29	1.4k	1.2k	1.0k	584	507	125	3.3k
J.C. Soria France	21	980 0.7×	1.4k 1.1×	1.0k 1.0×	528 0.9×	529 1.0×	124	2.8k
Jean‐Pascal Machiels Belgium	29	1.1k 0.8×	1.6k 1.3×	806 0.8×	482 0.8×	338 0.7×	137	3.1k
Madhusmita Behera United States	28	1.3k 0.9×	1.9k 1.6×	684 0.7×	374 0.6×	504 1.0×	131	3.2k
Fariba Navid United States	31	1.3k 0.9×	896 0.7×	686 0.7×	298 0.5×	318 0.6×	104	2.8k
Kathryn A. Gold United States	29	1.8k 1.3×	2.1k 1.8×	922 0.9×	463 0.8×	297 0.6×	99	3.5k
Charu Aggarwal United States	35	1.9k 1.3×	2.6k 2.2×	889 0.9×	801 1.4×	469 0.9×	202	4.1k
Alan H. Bryce United States	26	1.3k 0.9×	1.0k 0.9×	642 0.6×	545 0.9×	199 0.4×	167	2.5k
Peter Langmuir United States	30	1.6k 1.1×	1.8k 1.5×	1.3k 1.3×	507 0.9×	888 1.8×	56	4.7k
Takeshi Hanagiri Japan	35	1.8k 1.3×	1.8k 1.5×	1.2k 1.2×	448 0.8×	1.0k 2.0×	207	3.9k
Tommaso De Pas Italy	33	2.1k 1.5×	2.5k 2.1×	975 1.0×	620 1.1×	479 0.9×	151	4.3k

Countries citing papers authored by Jacques Médioni

Since Specialization

Citations

This map shows the geographic impact of Jacques Médioni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacques Médioni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacques Médioni more than expected).

Fields of papers citing papers by Jacques Médioni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacques Médioni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacques Médioni. The network helps show where Jacques Médioni may publish in the future.

Co-authorship network of co-authors of Jacques Médioni

This figure shows the co-authorship network connecting the top 25 collaborators of Jacques Médioni. A scholar is included among the top collaborators of Jacques Médioni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacques Médioni. Jacques Médioni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Canellas, A., Pauline du Rusquec, Isabelle Cojean-Zelek, et al.. (2025). Pneumopathies interstitielles diffuses liées au Trastuzumab Deruxtecan : résultats d’une large cohorte française en vie réelle chez des patients atteints de cancer du sein HER2-dépendant et autres tumeurs. Revue des Maladies Respiratoires Actualités. 17(1). 29–30.

Médioni, Jacques, et al.. (2025). Safety and efficacy of combined trastuzumab-deruxtecan and concurrent radiation therapy in breast cancer. The TENDANCE multicentric French study. The Breast. 80. 104421–104421. 3 indexed citations

Borrego, Manuel Ruíz, Isabel Blancas, Laia Garrigós, et al.. (2025). 294MO Preoperative window-of-opportunity study with giredestrant or tamoxifen (tam) in premenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) and Ki67≥10% early breast cancer (EBC): The EMPRESS study. Annals of Oncology. 36. S305–S305. 1 indexed citations

Médioni, Jacques, et al.. (2022). POSB397 Benefits of Homeopathic Complementary Treatment in Breast Cancer Patients: A Retrospective Cohort Study Based on the French Nationwide Healthcare Database (SNDS). Value in Health. 25(1). S258–S258.

Puszkiel, Alicja, Benoı̂t Blanchet, Nicolas Delanoy, et al.. (2021). Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study. Pharmaceuticals. 14(8). 804–804. 16 indexed citations

Koual, Meriem, Géraldine Perkins, Nicolas Delanoy, et al.. (2020). Syndrome héréditaire de prédisposition au cancer du sein et de l’ovaire : diagnostic et implications thérapeutiques. Annales de Pathologie. 40(2). 70–77. 1 indexed citations

Rosenbaum, Pierre, Cécile Artaud, Sylvie Bay, et al.. (2020). The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients. Cancer Immunology Immunotherapy. 69(5). 703–716. 41 indexed citations

Médioni, Jacques, Gisèle Pickering, C. Delorme, et al.. (2019). Prise en charge médicamenteuse des douleurs neuropathiques périphériques liées au cancer : une revue systématique de la littérature. Bulletin du Cancer. 106(9). 784–795. 2 indexed citations

Elaidi, Réza, Yann Vano, Nicolas Aide, et al.. (2016). Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride in renal cell carcinoma patients with bone metastases. Annals of Oncology. 27. vi295–vi295. 36 indexed citations

10.

Médioni, Jacques, Mario Di Palma, Aline Guillot, Dominique Spaëth, & Christine Théodore. (2016). Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study. BMC Cancer. 16(1). 217–217. 15 indexed citations

11.

Médioni, Jacques, Jean‐Paul Guastalla, & Ludovic Drouet. (2012). Thrombose veineuse et cancer du sein. Bulletin du Cancer. 99(2). 199–210. 5 indexed citations

12.

Adotévi, Olivier, Hélène Péré, Patrice Ravel, et al.. (2010). A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients. Journal of Immunotherapy. 33(9). 991–998. 171 indexed citations

13.

Oudard, Stéphane, et al.. (2009). Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Expert Review of Anticancer Therapy. 9(6). 705–717. 31 indexed citations

14.

Thiam, R., Laure Fournier, Ludovic Trinquart, et al.. (2009). Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Annals of Oncology. 21(5). 936–941. 72 indexed citations

15.

Riquet, Marc, et al.. (2008). Cancer pulmonaire non à petites cellules : particularités chirurgicales en fonction de l'âge. Revue des Maladies Respiratoires. 18(2). 173–184.

16.

Oudard, Stéphane, et al.. (2005). [Prostate cancer: update].. PubMed. 92(10). 865–73. 1 indexed citations

17.

Dendale, R., Anne Vincent‐Salomon, Alexia Savignoni, et al.. (2003). Medullary breast carcinoma: Prognostic implications of p53 expression. The International Journal of Biological Markers. 18(2). 99–105. 13 indexed citations

18.

Sauvat, Frédérique, Sabine Sarnacki, Hervé J. Brisse, et al.. (2002). Outcome of suprarenal localized masses diagnosed during the perinatal period. Cancer. 94(9). 2474–2480. 77 indexed citations

19.

Médioni, Jacques, et al.. (2000). [New trends in assessment in anticancer treatments by phase II clinical trials].. PubMed. 87(7-8). 551–6. 3 indexed citations

20.

Médioni, Jacques, et al.. (1982). Bloc auriculo-ventriculaire et torsades de pointe après surdosage par le sotalol.. La Nouvelle presse médicale. 11(52). 3855–3855. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact